The document discusses various types of implanted insulin pumps, including open loop pumps controlled manually by the user and closed loop "artificial pancreas" pumps that automatically adjust insulin levels based on continuous glucose monitor (CGM) readings. It describes the components of an artificial pancreas device system (APDS), including the CGM, blood glucose meter, control algorithm, and infusion pump. It also covers fabrication methods for thin film insulin pumps using shape memory alloys, the importance of check valves, and a block diagram of an insulin pump system with a glucose sensor and microcontroller.
Various insulin pumps used to deliver insulin to the human body and its application along with its advantages and disadvantages are outlined in this presentation.
It includes information about Hybrid closed loop insulin delivery system-Artificial Pancreas.Its details and how insulin pump develops with the time.It also includes the information about companies which manufacturing pumps.Also includes info about diabetes mellitus.
Various insulin pumps used to deliver insulin to the human body and its application along with its advantages and disadvantages are outlined in this presentation.
It includes information about Hybrid closed loop insulin delivery system-Artificial Pancreas.Its details and how insulin pump develops with the time.It also includes the information about companies which manufacturing pumps.Also includes info about diabetes mellitus.
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
It sense the blood glucose level, determining the amount of insulin needed, and then delivering the appropriate amount of insulin.
Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
The first hybrid closed loop system, the Medtronic's MiniMed 670G System is the first FDA approved artificial pancreas.
The FDA approved it for treating type 1 diabetes in people age 14 and older.
Artificial pancreases hit the market in 2016.
2018 Update in Diabetes Technology: Closed Loop, CGM, and MoreAaron Neinstein
A 2018 update in diabetes technology, including closed loop insulin delivery, continuous glucose monitoring, and more. Presented by Dr. Aaron Neinstein, faculty in Endocrinology at UCSF, at the UCSF Diabetes CME course in San Francisco, in April 2018.
Vanita R. Aroda, MD, prepared type 2 diabetes mellitus infographics for this CME activity titled, "Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus." For the full presentation, downloadable infographics, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2kdVkuJ. CME credit will be available until September 12, 2020.
This presentation is intended to allied health professional to have a overview of different types of insulin. It is meant to be a memory refresh. It was presented as part of continuing medical education session
This presentation was authored by Meaghan Anderson MS RD LD CDE, Senior Diabetes Clinical Manager-Houston North - Medtronic Diabetes specially for the Advanced Diabetes Seminar at TLC on April 26, 2014.
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
It sense the blood glucose level, determining the amount of insulin needed, and then delivering the appropriate amount of insulin.
Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
The first hybrid closed loop system, the Medtronic's MiniMed 670G System is the first FDA approved artificial pancreas.
The FDA approved it for treating type 1 diabetes in people age 14 and older.
Artificial pancreases hit the market in 2016.
2018 Update in Diabetes Technology: Closed Loop, CGM, and MoreAaron Neinstein
A 2018 update in diabetes technology, including closed loop insulin delivery, continuous glucose monitoring, and more. Presented by Dr. Aaron Neinstein, faculty in Endocrinology at UCSF, at the UCSF Diabetes CME course in San Francisco, in April 2018.
Vanita R. Aroda, MD, prepared type 2 diabetes mellitus infographics for this CME activity titled, "Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus." For the full presentation, downloadable infographics, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2kdVkuJ. CME credit will be available until September 12, 2020.
This presentation is intended to allied health professional to have a overview of different types of insulin. It is meant to be a memory refresh. It was presented as part of continuing medical education session
This presentation was authored by Meaghan Anderson MS RD LD CDE, Senior Diabetes Clinical Manager-Houston North - Medtronic Diabetes specially for the Advanced Diabetes Seminar at TLC on April 26, 2014.
A novel implantable dual microelectrode for monitoring/predicting post trauma...dharmakarma
Here, we describe a novel dual microelectrode concept based on brain oxygenation that can be used to predict seizures caused due to traumatic brain injury. Since brain oxygenation occurs slightly prior to chaotic neural firing, it can be used to predict in advance the occurrence of a seizure.
The DANA R insulin pump helps maintain
normal glucose levels discretely using
the ANYDANA application - now available for
most Android smart phones.
The web based ANYDANA Program is being
developed so that the Any DANA application send
pump settings, history, and the patients’ data there.
Your physician could then review and analyze all of
the information and forward changes despite long
distance.
Aunque se dice que cada proyecto es un mundo, tras participar en proyectos desde 5 perspectivas diferentes ( administración, pyme, consultoría, empresa multinacional y startup) he llegado a 7 conclusiones comunes.
En esta charla trataré de explicar mis 7 conclusiones sobre management de equipos y proyectos técnicos. Entre otras cosas abordaremos la estimación, gestión de equipo, el rol de jefe de proyecto o el de responsable de producto.
Combining Cardiovascular, Respiratory and Neurobehavioral Endpoints for Effic...InsideScientific
An essential webinar for preclinical scientists that wish to learn how to integrate hemodynamic, respiratory and neurological measurements to study multiple biological systems simultaneously while benefiting from more efficient data collection and workflow in the laboratory.
In this case study webinar sponsored by Data Sciences International, Dr. Brian Roche of Charles River Laboratories and Jason Payseur of GlaxoSmithKline discuss advantages and challenges pertaining to the combination of physiologic monitoring technologies to collect respiratory, cardiovascular and neurological endpoints from a single animal subject.
Specifically, Dr. Roche presents an evaluation of the AllayTM restraint technology utilized in DSI Respiratory solutions versus other commonly used methods. Complimented with implantable telemetry, Dr. Roche shows how he examined the effects of each method on various cardiopulmonary parameters and discusses the benefits and challenges associated with the use of the AllayTM restraint. Jason Payseur presents his assessment of a novel rodent model that examines cardiovascular, respiratory and neurobehavioral endpoints at the same time. He investigates the surgical feasibility of this model and tests its reliability in measuring multiple physiologic endpoints using tool compounds with known physiological effects, caffeine and chlorpromazine.
Continuous Glucose Monitoring for Diabetes, Obesity and Metabolism Research i...InsideScientific
Historically, diabetes, obesity and metabolism research has focused on acute metabolic testing characterized by infrequent sampling methods. This research contributes critical information regarding glucose metabolism and homeostasis; however, the acute approach and low sampling frequency leaves critical gaps in glucose metabolism research findings.
In this exclusive webinar sponsored by Data Sciences International, we present a new method of continuously monitoring blood glucose via implantable telemetry. Using case studies, we explore how a complete glucose profile can be observed while also reducing animal stress and associated labor for the scientist. Dr. Ralf Dechend (Max Delbruck Center for Molecular Medicine) presents a method of glucose monitoring in a novel pregnant rat model of type 2 diabetes and shares realized advantages pertaining to this new continuous approach. In addition, Christian Schnell (Novartis) discusses the value of continuous glucose data in the application of pharmacokinetics and pharmacodynamics while testing an oncology compound.
Today developments in the healthcare industry, especially the integration of Artificial Intelligence (AI), have revolutionised the future of diabetes treatment. As technology and research continue to progress, it shows clearly that the future of diabetes is now.
The application of AI to diabetes treatment and management has been one of the key advancements that have molded the future of diabetes treatment in today’s time
The future of diabetes treatment is indeed promising and we can expect more and more innovations coming into existence. Scientists are already speculating about the involvement of nanotechnology in the future of diabetes research.
LOW-COST INSULIN PUMP WITH PREDICTIVE BASED MITIGATION OF HYPERGLYCEMIA AND H...robelegemechu1
Diabetes Mellitus (DM) is considered a global epidemic. Type 1 diabetes(T1D) is an
autoimmune disease. The immune system attacks and destroys beta cells one of islet cell
in the pancreas, where insulin is made. They need exogenous insulin for the survival.
When characterizing medical devices in the field of diabetes technology, accuracy and
precision is always an aspect of interest. Insulin pumps, as opposed to other types of
insulin delivery systems, allow automatic infusion of minimal amounts of insulin on a
nearly continuous basis, the so-called basal rate, in addition to manual bolus injections.
In the last 30 years there have been great advances in technology for diabetes treatment,
which facilitated the management of the disease and its complications. However, diabetes
treatment using the insulin pump still remains expensive in Ethiopia, especially because
the device and its accessories are all imported. The aim of this thesis proposal is to
develop a prototype of a low-cost insulin infusion pump where the system actually
delivers the intended dose with accuracy. We will then perform a quantitative in vitro test
to assess the accuracy and reliability of the insulin infusion pump prototype, using a
method which estimates the displacement of the syringe plunger in response to
programmed infusions.
Insulin doses must be finely tuned in order to avoid dangerous complications. Insulin
under dosing can drive to hyperglycemia and an over dosing drives hypoglycemia. Thus,
a person with T1D is walking a tightrope between the risks of hypoglycemia and
hyperglycemia which makes insulin administration decisions difficult. The system we are
proposing can automatically suspend basal insulin delivery when it detects pending
hypoglycemia and automatically restarts basal insulin on recovery from hypoglycemia.
In addition to that, it can automatically dose basal insulin to hinder hyperglycemia
episodes caused by increase of glucose concentration which followed suspension event.
All of this will be accomplished with the use of prediction-based algorithm known as
kalman filter.
In the hospitals when any major operation is
performed, the patient must be in anesthetize condition. If the
operation lasts for a long time, for suppose for 4 or 5 hours,
complete dose of anesthesia cannot be administered in a single
stroke. It may lead to the patient’s death. If lower amount of
anesthesia is administered, the patient may wake up at the
middle of the operation. To avoid this, the anesthetist
administers few milliliters of anesthesia per hour to the
patient. If the anesthetist fails to administer the anesthesia to
the patient at the particular time interval, other allied
problems may arise. To overcome such hazardous problems
the design of an automatic operation of an anesthesia machine
based on a micro-controller is effective.
ORIGINAL ARTICLEThe Hybrid Closed-Loop SystemEvolution .docxalfred4lewis58146
ORIGINAL ARTICLE
The Hybrid Closed-Loop System:
Evolution and Practical Applications
Kathryn W. Weaver, MD, and Irl B. Hirsch, MD
Abstract
Achievement of well-controlled blood glucose is essential for preventing complications in patients with type 1
diabetes. Since the inception of continuous subcutaneous insulin infusion, the aim has been to develop an
artificial pancreas, with the ability to use an automated algorithm to deliver one or more hormones in response
to blood glucose with the intent to keep blood sugar as close to a prespecified target as possible. Development
and rapid improvement of continuous glucose sensor technology has recently allowed swift progress toward a
fully closed-loop insulin delivery system. In 2017, Medtronic began marketing the 670G insulin pump with
Guardian 3 sensor. When in auto mode, this is a hybrid closed-loop insulin delivery system that automatically
adjusts basal insulin delivery every 5 min based on sensor glucose to maintain blood glucose levels as close to a
specific target as possible. Patients receive prandial insulin by entering carbohydrate amount into the bolus
calculator. Early studies show improvement in HbA1c in both adults and adolescents with this technology.
Initial safety trials showed no occurrence of diabetic ketoacidosis or hypoglycemia. The utility of this device is
limited by blood glucose targets of 120 and 150 mg/dL that are unacceptably high for some patients. Not-
withstanding recent advances, we are far from a system that is able to replicate islet function in the form of a
fully automated, multihormonal blood glucose control device.
Keywords: Type 1 diabetes, Hybrid closed-loop, Artificial pancreas, Continuous subcutaneous insulin infusion,
670G.
Introduction
People with type 1 diabetes mellitus face a perpetualuphill battle in achieving optimal glycemic control. The
fine line between preventing hypoglycemia and avoiding
complications from hyperglycemia is challenging to navigate.
Our objective is to describe the history of continuous sub-
cutaneous insulin infusion (CSII) and continuous glucose
monitor (CGM) and how these components allowed the de-
velopment of the first commercially available ‘‘artificial pan-
creas’’ (AP), although many would prefer the nomenclature of
‘‘closed-loop insulin delivery.’’ We then go on to describe
practicalities of the initial hybrid closed-loop (HCL) insulin
delivery system released by Medtronic.
Since the first use of CSII in the late 1970s, real-time
CGM in the early 2000s, and the eventual sensor-augmented
pump and ‘‘low-glucose suspend’’ after that, the obvious
next step was further integration between the two for a
closed-loop system, which ideally would require minimal
interaction from the patient. The accuracy of the sensors has
only recently become adequate to safely move this tech-
nology forward.
Devices designed to mimic pancreatic endocrine function
have been under development since the 1970s. Initial sys-
tems
1,2
were.
PROJECTS SYNOPSIS BIOMEDICAL:Bed side patient monitoring system with automati...ASHOKKUMAR RAMAR
PROJECT CENTER TAMBARAM,PROJECT CENTER GUINDY, PROJECT CENTER PALLAVARAM,
PROJECT CENTER VELACHERRY, PROJECT CENTER CHROMPET, PROJECT CENTER VADAPALANI,PROJECT CENTER CHENNAI,
FINAL YEAR PROJECTS TAMBARAM,BEST PROJECT CENTER TAMBARAM,EMBEDDED SYSTEM PROJECTS, EMBEDDED PROJECTS TAMBARAM,
IEEE PROJECTS, IEEE PROJECTS TAMBARAM,
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
2. What is Implanted Insulin
Pump
An implanted insulin pump is a pump which remains inside the body at
all times. An implanted insulin pump is able to deliver insulin into the
peritoneal cavity which has a rich supply of blood vessels and can
therefore absorb insulin very efficiently
3. Types of pumps
Open loop pumps
• The insulin pump is controlled by the
user to bolus manually based on a
recent blood glucose measurement
and an estimate of the grams of
carbohydrate consumed. This
predictive approach is said to be
open-loop .Once a bolus has been
calculated and delivered, the pump
continues to deliver its basal rate
insulin in the manner that has been
programmed into the pump which
controls based on the predicted
insulin requirements of its user.
Closed loop pumps
• A closed-loop insulin delivery system
is essentially an artificial pancreas.
The loop refers to the continuous
cycle of feedback information, the
blood glucose level changes. this
change is detected by the continuous
glucose monitor (CGM). then CGM
sends information to the insulin
pump, which adjusts its insulin output
and the blood glucose level changes
again in response to the insulin. The
loop is closed when this happens
automatically
4. What is APDS?
An artificial pancreas device system (also known
as an APD system, AP or APDS) is a small,
portable medical device that is being designed
to carry out the function of a healthy pancreas
in controlling blood glucose levels. It uses digital
communication technology to automate insulin
delivery. An APD system is worn externally on
the body, and is made up of three functional
components:
A. A continuous glucose monitor (CGM),A
digital controller, An insulin pump .
B. the CGM and insulin pump are linked
together for the first time by a digital
controller device (the ‘brain’ or ‘control
centre’) containing a control algorithm. An
algorithm is a set of rules by which
information can be quickly processed
through a series of steps to arrive at a
logical decision about what needs to be
done next. Algorithms are usually written
out as a set of mathematical equations, and
are used quite widely in medicine to help
healthcare professionals reach logical and
consistent decisions about patient care
when the information going into that
decision is complex.
5. Components and its
working
(1) Continuous Glucose Monitor (CGM).-A CGM
provides a steady stream of information that is
intended to reflect the patient’s blood glucose levels. A
sensor placed under the patient's skin (subcutaneously)
measures the glucose in the fluid around the cells
(interstitial fluid), which has been found to correlate
with blood glucose levels. A small transmitter sends
information to a receiver. A CGM continuously displays
both an estimate of blood glucose levels and their
direction and rate of change of these estimates.
(2)Blood Glucose Device (BGD)- Currently, to get the
most accurate estimates of blood glucose possible from
a CGM, the patient needs to periodically calibrate the
CGM using a blood glucose measurement from a BGD,
therefore, the BGD still plays a critical role in the proper
management of patients with an APDS. However, over
time, we anticipate that improved CGM performance
may obviate the need for periodic blood glucose checks
with a BGD.
(3) APDS Control algorithm-An APDS control algorithm
is software embedded in an external processor
(controller) that receives information from the CGM
and performs a series of mathematical calculations.
Based on these calculations, the controller sends
dosing instructions to the infusion pump.
(4) Infusion pump- Based on the instructions sent by
the controller, an infusion pump adjusts the insulin
delivery to the subcutaneous tissue.
(5) The Patient-The patient is an important part of the
APDS. The concentration of glucose circulating in the
patient’s blood is constantly changing. It is affected by
the patient’s diet, activity level, and how his or her
body metabolizes insulin and other substances.
6. VAPOUR PRESSURE
PUMP MECHANISM
The driving force generated by gas vapour
(usually Freon).Consists of two chambers :
stored insulin and vapor system.Vapour in a
compartment will push against bellow
chamber that contains insulin. Pressure
against bellow is constant regardless of
amount of insulin. Infusion rate is
determined by an outflow restrictor. Based
on diagram in previous slide, there is two
outflow restrictor.When valve activated, one
of the flow restrictor will be bypassed. If
valve not activated, insulin will still flow out
but infusion rate is restricted. Thus, insulin
will be continuously delivered. The amount
of insulin (i.e. infusion rate) depends on
outflow restrictor. No parts giving rise to
friction. No need of electrical energy for
pumping. But care must be taken in the
vapor pressure. Pressure might rise due to
ambient pressure and other factors. This
might lead to uncontrollable infusion.
7. Fabrication of thin film
insulin pump
I. Sputtered films of nickel-titanium are first
deposited on a silicon wafer.
II. After sputtering, the backside of the silicon
substrate is etched away exposing a small area of
the alloy film. This area is then hot deformed at
480C by a spherically pointed probe.
III. In typical actuators a shape memory alloy spring
is opposed by a conventional spring. When
heated the shape memory spring expands,
overcoming the bias spring and exerting some
output force.
IV. For the case of the thin film diaphragm, which is
to change from a flat to a dome shape to create a
pumping action, some form of biasing force is
also required.
V. By manipulating the sputtering process a thin
film can be deposited with a composition
gradient varying from equiatomic nickel-titanium
to a nickel rich composition. The equiatomic film
exhibits shape memory and the high nickel part
of the film acts as a restraining force or bias.
VI. When this composite film is deformed at a high
temperature, this shape is imprinted in the film.
When the film cools the bias layer forces the film
into the flat position, but when the film is heated
it returns to the dome shape imprinted by the
hot deformation process. The sequence of the
processes to produce a single thin film diaphragm
pump is given in fig .
8. Importance of Check
valves
Check valves for microfluidic devices are of
two types are ball check and disc. The ball
check valves have excellent sealing against
reverse flow and unrestricted flow in the
positive direction; however, they are fairly
large in terms of the pump body volume
envisioned, although miniaturization is
possible.
The disc type valve is smaller, has good back
flow characteristics and excellent forward
flow and does not easily foul.they also can
fabricate in an even smaller version on
special order. If the available check valves do
not suite the envelope required, flapper
valves photoetched from a silicon substrate
can be explored; these been used in fluidic
control systems.
9. The control system
The control system will consist of the following: a precision 0.01% temperature compensated
voltage reference for sensor excitation, analog input operational amplifiers to raise the sensor
voltage signal to a more useful value, MOSFET switches for switching DC power to the thin film
diaphragms and for switching analog signals, and a sophisticated micro-controller with analog to
digital conversion, serial communications, high current output channels and all needed support
circuitry, including “sleep timer” and EEPROM. The insulin pump will be controlled by a standard
PID control algorithm. The Proportional-Integral-Differential control is broadly used where
system response can lag behind the control output by a significant amount of time, ranging from
milliseconds to tens of minutes. Tuning the PID algorithm can be carried out to accommodate
the variation in drug delivery rate required. For the insulin pump the rate must be controllable
to match the wide types of insulin which might be used, with the objective of minimizing
divergence of glucose levels from the desired 5.6 mmol/l.
10. The Glucose sensor
Glucose monitoring system measure hydrogen peroxide.
Hydrogen peroxide produced by the enzymatic reaction of glucose at the site
of the immobilized glucose oxidase membrane.
Glucose + O2 → Gluconiuc acid + H2O2
For needle type glucose sensor, sensor consisting of a platinum anode and a
silver cathode.
The electrodes, loaded with 0.6 V polarographic voltage, measure hydrogen
peroxide.
Needle-type glucose sensors were inserted into the subcutaneous tissue of the
forearm or the abdomen
11. Block Diagram of
Insulin Pump
The system consists of a glucose sensor strip
to measure the glucose level and the
electrical signal obtained was amplified and
fed to the micro controller. The micro-
controller reads the current glucose level and
calculates the amount of insulin required
based on the treatment parameters set by
the physician and this quantity of insulin is
then pumped into the patient’s blood. The
microcontroller is programmed in such a way
that the blood glucose level is monitored at a
time interval of 2 hours and the data is read
by the micro controller (also, the pump
permits possibility for measuring blood
glucose level at other intervals according to
patient’s requirement). Revised and
appropriate quantity of insulin is again
pumped and this process repeats to maintain
the desired level of glucose in the patient’s
blood.
13. Advantages and Disadvantages of insulin
pump
Pros
• Less jabs
• Take insulin as and when you need it
• Have different basal rates at different times
of the day
• Flexibilty with food
• Flexibitity with exercise
• Increase blood glucose control
• Reducing episodes of severe hypoglycaemia
Cons
• Difficult getting a pump on NHS
• Cost: if buying by yourself
• Steep learning curve
• Frequent blood testing required
• Changing infusion set more difficult than
changing injection
• Risk of diabetic ketoacidosis
• Skin infection
• Tubing of insulin pumps getting caught on
objects
14. Application in treatment of type
2 diabetes patient
5 patients with Type II diabetes by means of a subcutaneously implanted
intravenous insulin pump and compared their metabolic response with that
observed during conventional insulin therapy. The use of the pump improved
control of glycaemia, as manifested by reductions in mean plasma glucose
(from 188±46 to 106±12 mg per decilitre ), fasting glucose (from 187±42 to
80±13 mg per decilitre), and postprandial glucose (from 287±74 to 182±29 mg
per decilitre), together with a diminution of glycaemic excursion and
normalization of glycosylated haemoglobin A1 (from 12.1 ±2 to 8.0±1 per cent).
At the end of the study the pumps had been in place for a mean of 7.0 months
(range, 5.5 to 9.7 months) without mishap and with good patient acceptance.
Improved blood glucose control can be achieved by means of a permanently
implanted continuous insulin-infusion device in ambulatory patients with Type
II diabetes who require insulin, and that the need for daily insulin injections
can thereby be eliminated.